Provided by Tiger Trade Technology Pte. Ltd.

CureVac B.V.

4.66
0.0000
Volume:- -
Turnover:5.32M
Market Cap:1.05B
PE:6.93
High:4.66
Open:4.66
Low:4.66
Close:4.66
52wk High:5.72
52wk Low:2.48
Shares:225.17M
Float Shares:125.87M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6720
EPS(LYR):0.7483
ROE:16.43%
ROA:11.72%
PB:1.02
PE(LYR):6.23

Loading ...

Evotec SE Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations

Reuters
·
Jan 02

European Stocks Set to Close Higher in Thursday Trading; ECB Maintains 3 Key Interest Rates; England Cuts Rate by Quarter Point

MT Newswires Live
·
Dec 19, 2025

Biontech Closes Acquisition Of CureVac

Reuters
·
Dec 18, 2025

BioNTech Closes Acquisition of CureVac

Reuters
·
Dec 18, 2025

CureVac Down Over 12%, on Pace for Largest Percent Decrease in Almost Two Years -- Data Talk

Dow Jones
·
Dec 18, 2025

BioNTech Secures 81.7% of CureVac Shares in Tender Offer

Reuters
·
Dec 03, 2025

Can New Board Leadership at CureVac (CVAC) Shift the Narrative After Recent Earnings Decline?

Simply Wall St.
·
Dec 01, 2025

BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025

Reuters
·
Nov 26, 2025

BioNTech shares update on exchange offer for CureVac shares

TIPRANKS
·
Nov 26, 2025

CureVac NV Held Extraordinary General Meeting

Reuters
·
Nov 26, 2025

Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher

Benzinga
·
Nov 24, 2025

CureVac Q3 EPS $1.41 Beats $(0.17) Estimate, Sales $63.295M Beat $14.520M Estimate

Benzinga
·
Nov 24, 2025

Update: CureVac Q3 Earnings, Revenue Fall; German Regulators Clear BioNTech Acquisition

MT Newswires Live
·
Nov 24, 2025

CureVac reports Q3 EPS EUR 1.21 vs. EUR 1.51 last year

TIPRANKS
·
Nov 24, 2025

Earnings Flash (CVAC) CureVac Posts Q3 EPS 1.21 Euros

MT Newswires Live
·
Nov 24, 2025

BioNTech Offer for CureVac Shares Enters Final Phase After Regulatory Clearance

Reuters
·
Nov 24, 2025

Curevac Reaffirms Its Expected Cash Runway Into 2028

Reuters
·
Nov 24, 2025

CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million

Reuters
·
Nov 24, 2025

CureVac Nv - Company Reaffirms Its Expected Cash Runway Into 2028

THOMSON REUTERS
·
Nov 24, 2025

CureVac Nv - Net Financial Result for Three and Nine Months Ended September 30, 2025, Was Loss of EUR 2.6 Mln and Gain of EUR 2.2 Mln, Respectively

THOMSON REUTERS
·
Nov 24, 2025